Department of Hematology, Oncology and Tumor Immunology, Charité Universitätsmedizin Berlin, Germany.
Department of Medicine II, Hematology/Oncology, Goethe University, Frankfurt/Main, Germany.
Haematologica. 2017 Oct;102(10):1739-1747. doi: 10.3324/haematol.2016.161273. Epub 2017 Jul 27.
Genetic alterations of the transcription factor IKZF1 ("IKAROS") are detected in around 15-30% of cases of -negative B-cell precursor acute lymphoblastic leukemia. Different types of intragenic deletions have been observed, resulting in a functionally inactivated allele ("loss-of-function") or in "dominant-negative" isoforms. The prognostic impact of these alterations especially in adult acute lymphoblastic leukemia is not well defined. We analyzed 482 well-characterized cases of adult -negative B-precursor acute lymphoblastic leukemia uniformly treated in the framework of the GMALL studies and detected alterations in 128 cases (27%). In 20%, the alteration was present in a large fraction of leukemic cells ("high deletion load") while in 7% it was detected only in small subclones ("low deletion load"). Some patients showed more than one alteration (8%). Patients exhibiting a loss-of-function isoform with high deletion load had a shorter overall survival (OS at 5 years 28% 59%; <0.0001), also significant in a subgroup analysis of standard risk patients according to GMALL classification (OS at 5 years 37% 68%; =0.0002). Low deletion load or dominant-negative alterations had no prognostic impact. The results thus suggest that there is a clear distinction between loss-of-function and dominant-negative deletions. Affected patients should thus be monitored for minimal residual disease carefully to detect incipient relapses at an early stage and they are potential candidates for alternative or intensified treatment regimes. ().
转录因子 IKZF1(“IKAROS”)的遗传改变在约 15-30%的 -阴性 B 细胞前体急性淋巴细胞白血病病例中被检测到。已经观察到不同类型的基因内缺失,导致功能失活的等位基因(“功能丧失”)或“显性负”同工型。这些改变在成人急性淋巴细胞白血病中的预后影响尚不清楚。我们分析了 482 例经过 GMALL 研究框架统一治疗的特征明确的成人 -阴性 B 前体急性淋巴细胞白血病病例,在 128 例(27%)中检测到了改变。在 20%的病例中,改变存在于大量白血病细胞中(“高缺失负荷”),而在 7%的病例中仅在小亚克隆中检测到(“低缺失负荷”)。一些患者表现出不止一种改变(8%)。具有高缺失负荷的功能丧失同工型的患者总生存时间较短(5 年 OS 为 28% 59%;<0.0001),在 GMALL 分类标准风险患者的亚组分析中也有显著差异(5 年 OS 为 37% 68%;=0.0002)。低缺失负荷或显性负性改变无预后影响。因此,结果表明存在功能丧失和显性负性缺失之间的明显区别。受影响的患者应仔细监测微小残留病,以早期发现即将复发的情况,他们是替代或强化治疗方案的潜在候选者。